Successful planned IDMC review of ACTION3 trial
Filed with ASX · · 3 pages · English
Earlier from Dimerix
- Dimerix receives initial upfront payment from Amicus
- Investor Webinar and Presentation
- Dimerix Licenses DMX-200 in the US
- Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United States
- Trading Halt
Later from Dimerix
- 1st ACTION3 site in Japan activated and milestone triggered
- ACTION3 Clinical Trial Milestone Recruitment Update
- Dimerix receives 1st Development Milestone payment from FUSO
- Appendix 4E and 2025 Annual Report
- DMX-200 receives Orphan Drug Designation in Japan
Follow Dimerix into a list and get an email when it puts out news.
Follow Dimerix